10-Q: Surgery Partners Reports Mixed Q2 Results Amidst Strategic Acquisitions and Debt Refinancing

Surgery Partners' second quarter saw revenue growth driven by same-facility performance and acquisitions, but a net loss was reported due to increased expenses and debt extinguishment costs.

Summary

• Surgery Partners reported a 14.2% increase in total revenue for the second quarter of 2024, reaching $762.1 million, compared to $667.6 million in the same period of 2023.
• The revenue growth was attributed to a 9.9% increase in days adjusted same-facility revenues, which included a 5.7% increase in revenue per case and a 3.9% increase in same-facility cases.
• Adjusted EBITDA for the second quarter of 2024 increased by 18.1% to $118.3 million, up from $100.2 million in the second quarter of 2023.
• However, the company reported a net loss attributable to common stockholders of $15.5 million for the second quarter of 2024, compared to a net income of $18.9 million in the same period of 2023.
• The net loss was primarily due to increased operating expenses, transaction and integration costs, and a loss on debt extinguishment.
• During the quarter, Surgery Partners acquired controlling interests in six surgical facilities and several physician practices for $264.6 million in cash and $1.1 million in non-cash consideration.
• The company also sold a non-controlling interest in one surgical facility for $2.0 million and a portion of its interest in another facility for $2.5 million.
• Surgery Partners refinanced its debt, issuing $800 million in senior unsecured notes due 2032 and entering into a new $1.4 billion term loan agreement.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows strong revenue and EBITDA growth, the net loss and increased expenses raise concerns. The strategic acquisitions and debt refinancing are positive, but the overall financial performance is mixed.

Positives

• The company experienced strong revenue growth, driven by both same-facility performance and strategic acquisitions.
• Adjusted EBITDA showed significant improvement, indicating enhanced operational efficiency and cost management.
• The successful debt refinancing provides the company with a more favorable capital structure and extends debt maturities.
• The company continues to expand its network through strategic acquisitions of surgical facilities and physician practices.

Negatives

• The company reported a net loss attributable to common stockholders of $15.5 million for the second quarter of 2024.
• Increased operating expenses, transaction and integration costs, and a loss on debt extinguishment contributed to the net loss.
• Interest expense, net, was $51.5 million for the three months ended June 30, 2024, compared to $47.7 million for the same period in 2023.
• The company incurred $19.3 million of transaction and integration costs for the three months ended June 30, 2024, compared to $12.0 million for the same period in 2023.

Risks

• The company is subject to risks related to reductions in payments from government health care programs and private insurance payors.
• Failure to maintain or develop relationships with physicians could negatively impact the business.
• The company faces competition for physicians, nurses, strategic relationships, acquisitions, and managed care contracts.
• Cybersecurity attacks or intrusions could have a material adverse effect on the business.
• Broad economic factors, including increases in interest rates, inflation, and supply chain risks, could negatively affect the company's performance.
• The company's indebtedness could impact its ability to access capital and repay outstanding debt.

Future Outlook

The company continues to focus on improving same-facility performance, selectively acquiring established facilities, developing new facilities, and other portfolio management initiatives. They believe cash flows from operations, available cash, available capacity on their Revolver, and continued anticipated access to capital markets will be adequate to meet their short-term and long-term liquidity needs.

Management Comments

• Management stated that the increase in revenues was attributable to same-facility revenue growth and the net impact from acquisitions and divestitures.
• Management noted that the increase in Adjusted EBITDA was primarily attributable to revenue growth, continued cost management initiatives, and acquisitions completed since the prior year period.
• Management believes that cash flows from operations, available cash, available capacity on the Revolver, and continued anticipated access to capital markets will be adequate to meet short-term and long-term liquidity needs.

Industry Context

The announcement reflects the ongoing trend of consolidation and strategic acquisitions within the healthcare industry, particularly in the ambulatory surgery center sector. The company's focus on multi-specialty facilities and physician partnerships aligns with industry efforts to enhance efficiency and patient access to care. The debt refinancing is a common strategy to optimize capital structure in a rising interest rate environment.

Comparison to Industry Standards

• Surgery Partners' revenue growth of 14.2% in Q2 2024 is above the average growth rate for the healthcare services sector, which has seen moderate growth due to various factors including reimbursement pressures and changing patient volumes.
• The company's Adjusted EBITDA growth of 18.1% is also strong compared to industry peers, indicating effective cost management and operational improvements.
• However, the net loss reported by Surgery Partners contrasts with some of its competitors who have reported profits, suggesting that the company's integration and debt management costs are impacting its bottom line.
• Companies like Tenet Healthcare and HCA Healthcare, which also operate hospitals and ambulatory surgery centers, have reported varying results, with some showing stronger profitability but slower revenue growth.
• The debt refinancing undertaken by Surgery Partners is similar to actions taken by other healthcare companies to manage their capital structure in response to rising interest rates, but the specific terms and impact on the company's financials will need to be monitored.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices, and personal injuries.
• The company is not aware of any proceedings that are reasonably possible to have a material adverse effect on its business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders may be concerned about the net loss, but encouraged by the revenue and EBITDA growth.
• Employees may be affected by the retirement of a key executive and the implementation of a new deferred compensation plan.
• Customers (patients) may experience improved services due to the company's strategic acquisitions and facility development.
• Creditors may view the debt refinancing as a positive step towards financial stability.

Next Steps

• The company will continue to focus on improving same-facility performance.
• The company will continue to selectively acquire established facilities.
• The company will continue to develop new facilities.
• The company will continue to pursue other portfolio management initiatives.

Key Dates

Keywords

Surgery Partners, surgical facilities, ambulatory surgery centers, physician practices, acquisitions, debt refinancing, EBITDA, revenue growth, healthcare, financial results